Tirzepatide 30mg Peptide

Tirzepatide 30mg is a highly pure research peptide provided as a lyophilised product that can be used for further laboratory studies. Tirzepatide is an artificial peptide known for its dual agonist action on GIP and GLP-1 receptors, thus being an interesting object of study in the context of incretin signaling.
The content of each vial includes 30mg of Tirzepatide.

Tirzepatide 30mg – Dual Agonist Research Peptide

Tirzepatide, which was given the code name LY3298176 during development, is a novel 39-amino acid peptide created specifically to target the GIP and GLP-1 receptors.
The ability of Tirzepatide to target both GIP and GLP-1 receptors makes it distinct from other molecules which have been formulated to mainly target the GLP-1 receptor pathway. The property has made it a topic of interest in laboratory studies on receptor pharmacology and interactions.

Why Choose Tirzepatide 30mg?

The 30mg format provides a larger quantity of research material for laboratories whose experimental requirements extend beyond smaller vial sizes.
It may be suitable for research programmes involving multiple analytical procedures, comparative experiments or repeated investigations where maintaining material from the same batch is beneficial.
Using an appropriately sized vial can also simplify inventory management and help researchers maintain consistent batch records throughout a project. The quantity selected should always reflect the requirements of the individual experimental protocol.

Understanding Dual GIP and GLP-1 Activity

The defining molecular characteristic of Tirzepatide is its ability to activate both GIP and GLP-1 receptors.
GIP, or glucose-dependent insulinotropic polypeptide, forms part of the incretin signalling system and has long been investigated within metabolic research.
GLP-1, or glucagon-like peptide-1, represents another extensively researched incretin pathway.
Tirzepatide combines activity at both receptor systems within a single molecule, allowing researchers to investigate dual-receptor signalling and compare its molecular behaviour with compounds targeting only one incretin pathway.

99%+ Purity & Quality Documentation

Purity is an important consideration when sourcing peptides for controlled laboratory research. Tirzepatide 30mg is specified at 99%+ purity, providing clearly characterised research material for analytical applications.
Where supplied, researchers should consult the Certificate of Analysis (COA) associated with the specific production batch. Batch documentation can provide important information concerning identity, purity and analytical testing.
Laboratories should retain relevant batch numbers and documentation alongside experimental records to support traceability.